COMPARE
Four Peptides, Four Points on the Same Road
Same starting point — a peptide active pharmaceutical ingredient — four very different distances traveled toward approved, evidence-backed medicine.
The short version
All four peptides on this site began as active pharmaceutical ingredients — synthetic molecules engineered to act on an existing receptor system in the body. What separates them is how far each one has gone since: how many human trials exist, how broad the approval is (if any), and how confidently the safety picture is known.
Ranked by regulatory reach, the order runs semaglutide and tirzepatide (broad, multi-indication approval) ahead of tesamorelin (one narrow approval) ahead of BPC-157 (no approval, minimal human data). This page lays that progression out directly, compound by compound, so the differences are easy to see at a glance rather than buried inside four separate pages.
Mechanism, at a glance
| Compound | Receptor target(s) | Core proposed effect |
|---|---|---|
| Semaglutide | GLP-1 receptor | Glucose-dependent insulin release, appetite suppression via central nervous system circuits |
| Tirzepatide | GLP-1 receptor + GIP receptor | Same GLP-1 effects, amplified by a second receptor target; larger weight and glucose effects in trials |
| Tesamorelin | GHRH receptor (pituitary) | Stimulates the body's own pulsatile growth-hormone release, driving visceral-fat reduction |
| BPC-157 | Proposed VEGFR2/angiogenesis pathway | Promotes new blood-vessel growth, proposed basis for tissue-repair effects in animal models |
Semaglutide and tirzepatide sit in the same drug class — incretin mimetics — with tirzepatide simply engaging one more receptor. Tesamorelin works upstream of growth hormone rather than supplying it directly. BPC-157's mechanism is the least settled of the four; it is described in the literature as 'proposed' and 'best-characterized' rather than as an established pharmacological pathway the way GLP-1 receptor agonism is [20].
Regulatory status, at a glance
| Compound | FDA status | Scope of approval |
|---|---|---|
| Semaglutide | Approved | Type 2 diabetes, chronic weight management, cardiovascular risk reduction, MASH (2025) |
| Tirzepatide | Approved | Type 2 diabetes, chronic weight management, obstructive sleep apnea |
| Tesamorelin | Approved | HIV-associated lipodystrophy only — no other indication |
| BPC-157 | Not approved | No FDA-approved indication for any use; classified by the FDA as ineligible for pharmacy compounding pending further evaluation |
The gap between semaglutide/tirzepatide and tesamorelin is a gap in breadth — both categories have real approvals, but tesamorelin's covers one specific patient population. The gap between tesamorelin and BPC-157 is a gap in kind — one has been through the full trial-and-approval pathway for its indication, and one has not been through it for any indication at all.
Evidence maturity, at a glance
Semaglutide and tirzepatide each carry multiple large randomized controlled trials in the tens of thousands of participants combined, including head-to-head comparisons between them [1][3][4][10][11]. Tesamorelin's evidence base is smaller but still built on genuine randomized controlled trials and a supporting meta-analysis, concentrated in one patient population (HIV-associated lipodystrophy) [12][14][16]. BPC-157's evidence base is the outlier: extensive rodent and in-vitro research, but — per a 2025 narrative review — only three small human pilot studies, one of which is a two-person intravenous safety pilot [17][18].
None of this ranks the compounds by how 'good' or 'bad' they are. It describes how much confidence the published record currently supports for each one, in each one's own studied population — which is the single most useful thing a reader can know before drawing any conclusion from a single page or a single anecdote.
What each is actually studied for
It's worth being precise about what each compound has evidence for, because the four are not interchangeable even where they overlap. Semaglutide and tirzepatide are both studied primarily for metabolic and weight outcomes, with semaglutide additionally carrying dedicated cardiovascular and kidney-outcome trials [2][3][7]. Tesamorelin is studied specifically for visceral and hepatic fat reduction in HIV-associated lipodystrophy — a distinct population and a distinct fat depot from general weight management [12][14]. BPC-157's animal literature centers on gastric-ulcer healing and tissue/vascular repair, not on metabolic outcomes at all [20][21]. Reading across compounds for a shared theme (research peptides broadly) should not be mistaken for reading across compounds for a shared use case.